Capricor Therapeutics (CAPR) EBIT Margin (2011 - 2024)
Capricor Therapeutics' (CAPR) quarterly EBIT Margin came in at 69.15% in Q4 2024, down 5855.0% year-on-year from 1.2% in Q1 2024, and up 87.98% quarter-over-quarter from 575.24% in Q3 2024.
Capricor Therapeutics (CAPR) EBIT Margin (2011 - 2024) Analysis & Trends
Capricor Therapeutics' EBIT Margin history runs 13 years deep, the most recent figure standing at 69.15% for Q4 2024.
- On a quarterly basis, EBIT Margin fell 5855.0% year-over-year to 69.15% in Q4 2024; TTM through Sep 2025 was 778.78%, a 65114.0% decrease from a year earlier, with the FY2024 full-year figure at 191.12%, down 9549.0% from the prior year.
- EBIT Margin grew to 69.15% in Q4 2024 per CAPR's latest filing, from 575.24% in the prior quarter.
- Across five years, EBIT Margin topped out at 10.6% in Q4 2023 and bottomed at 23211.04% in Q3 2020.
- The 5-year median for EBIT Margin is 491.12% (2022), against an average of 3536.55%.
- Across the five-year window, EBIT Margin sank 2206537 bps in 2020 and jumped 450397 bps in 2021, its largest moves.
- Year by year, EBIT Margin stood at 7229.02% in 2020, then surged by 66 bps to 2490.75% in 2021, then soared by 66 bps to 840.33% in 2022, then soared by 99 bps to 10.6% in 2023, then tumbled by 552 bps to 69.15% in 2024.
- Per Business Quant, the three latest CAPR EBIT Margin figures stand at 69.15% (Q4 2024), 575.24% (Q3 2024), and 291.86% (Q2 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Capricor Therapeutics | 1.12 Bn | 1.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -69.15% |
| Sep 30, 2024 | -575.24% |
| Jun 30, 2024 | -291.86% |
| Mar 31, 2024 | -102.66% |
| Dec 31, 2023 | -10.60% |
| Sep 30, 2023 | -110.97% |
| Jun 30, 2023 | -197.76% |
| Mar 31, 2023 | -274.04% |
| Dec 31, 2022 | -840.33% |
| Sep 30, 2022 | -407.00% |
| Jun 30, 2021 | -2,490.75% |
| Mar 31, 2021 | -12,644.77% |
| Dec 31, 2020 | -7,229.02% |
| Sep 30, 2020 | -23,211.04% |
| Jun 30, 2020 | -6,994.72% |
| Mar 31, 2020 | -1,134.94% |
| Dec 31, 2019 | -667.88% |
| Sep 30, 2019 | -1,145.67% |
| Jun 30, 2019 | -503.39% |
| Mar 31, 2019 | -1,109.38% |